Psoriasis long term prognosis,

Karcsoport címke:. Daivonex® scalp solution Jogosultság Kritériumok: Inclusion Criteria: 1. Signed and dated informed consent has been obtained.

Subjects of either gender 18 years of age or above. Female of childbearing potential using a reliable method of contraception for at least 1 month before the trial start and during the course of the trial e.

Exclusion Criteria: 1. Current diagnosis of guttate, erythrodermic, exfoliative, or pustular psoriasis.

Clinical Research News

Subjects with any of the following conditions present on the scalp area: viral lesions, fungal and bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, rosacea, acne vulgaris, acne rosacea, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, ulcers, and wounds.

Systemic treatment with all other pikkelysömör kezelése udalyanchiban with a possible effect on psoriasis vulgaris e.

This study highlights data from two existing clinical trials to capture PASI 50 and PASI 75 responder rates which represent a common metric used in current psoriasis clinical trials. A review of pharmacokinetics, safety and a discussion of relapse rate establish acitretin as an efficacious, convenient, oral treatment for initial and maintenance therapy of severe psoriasis. Mechanism of action The efficacy of acitretin in psoriasis is mainly explained by the fact that this compound acts on a pathological epidermis to reduce proliferation and stimulate differentiation. It also decreases inflammation in the epidermis and dermis by interfering with various cytokines. However, in contrast to other systemic antipsoriatic drugs, acitretin is neither cytotoxic nor immunosuppressive.

PUVA therapy within 4 weeks prior to randomisation or during the trial. UVB therapy within 2 weeks prior to randomisation or during the trial. Therapies within 2 weeks prior to randomisation and during the trial: - Topical treatment of body psoriasis with very potent WHO group IV corticosteroids - Topical treatment of face psoriasis with potent or very potent WHO group III and IV corticosteroids - Any topical treatment of the scalp except for non-steroid medicated shampoos and emollients 8.

Known or suspected renal insufficiency or hepatic disorders or severe heart disease. Clinical signs or symptoms of Cushing's disease or Addison's disease.

Efficacy of Acitretin in Severe Psoriasis

Known or suspected hypersensitivity to component s of IMPs Current participation in any other interventional clinical trial Subjects who have received treatment with any non-marketed drug substance i. Previously participated in a clinical trial within 4 weeks prior to randomisation.

In the opinion of the sub investigator, the subject is unlikely to comply with the clinical trial protocol e. Females who are pregnant, or of child-bearing potential and wish to become pregnant during the trial, or who are breast-feeding.

Females of child-bearing potential with a positive urine pregnancy test at psoriasis long term prognosis 1.